27.85
0.16 (0.58%)
| 前收盘价格 | 27.69 |
| 收盘价格 | 27.83 |
| 成交量 | 116,932 |
| 平均成交量 (3个月) | 275,373 |
| 市值 | 860,910,144 |
| 价格/销量 (P/S) | 2.54 |
| 股市价格/股市净资产 (P/B) | 0.720 |
| 52周波幅 | |
| 利润日期 | 7 Nov 2025 |
| 营业毛利率 | -13.94% |
| 营业利益率 (TTM) | -26.95% |
| 稀释每股收益 (EPS TTM) | -1.33 |
| 季度收入增长率 (YOY) | 13.90% |
| 总债务/股东权益 (D/E MRQ) | 0.74% |
| 流动比率 (MRQ) | 6.32 |
| 营业现金流 (OCF TTM) | 9.36 M |
| 杠杆自由现金流 (LFCF TTM) | -42.21 M |
| 资产报酬率 (ROA TTM) | -3.69% |
| 股东权益报酬率 (ROE TTM) | -3.72% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 看涨 |
| Diagnostics & Research (全球的) | 看涨 | 看涨 | |
| 股票 | Fulgent Genetics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.30 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 33.42% |
| 机构持股比例 | 54.65% |
| 52周波幅 | ||
| 中 | 30.00 (7.72%) | |
| 总计 | 1 保留 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 11 Nov 2025 | 30.00 (7.72%) | 保留 | 28.38 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| GAO HANLIN | - | 27.53 | -1,331 | -36,642 |
| KIM PAUL | - | 27.53 | -3,004 | -82,700 |
| XIE JIAN | - | 27.53 | -4,711 | -129,694 |
| 累积净数量 | -9,046 | |||
| 累积净值 ($) | -249,036 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 27.53 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KIM PAUL | 职员 | 26 Jan 2026 | 处理 (-) | 3,004 | 27.53 | 82,700 |
| XIE JIAN | 职员 | 26 Jan 2026 | 处理 (-) | 4,711 | 27.53 | 129,694 |
| GAO HANLIN | 职员 | 26 Jan 2026 | 处理 (-) | 1,331 | 27.53 | 36,642 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 22 Dec 2025 | 公告 | Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合